New cholesterol drug reduces risk of heart attack
The results of a two-year clinical trial on the drug sold as Repatha by Amgen Phamaceuticals that costs more than USD 14,000 a year were released at the American College of Cardiology annual conference in the US capital.
Mar 18, 2017, 09:30 AM IST